

Table S1. Clinicopathological characteristics of 44 patients with gastric cancer

Characteristics	Number	Percent (%)
Age (year)		
< 60	15	34.1
≥ 60	29	65.9
Sex		
Man	34	77.3
Woman	10	22.7
Histologic type (Lauren)		
Diffuse	12	27.3
Intestine	13	29.5
Mixture	19	43.2
TNM stage		
II	10	22.7
III	20	45.5
IV	14	31.8

Table S2. The primers for q-PCR

Gene Name	Forward Primer (5'→3')	Reverse Primer (5'→3')
UBAP2L	ATGACATCGGTGGGCACTAAC	GTCAGCATCATTATGGTCCGAA
β-actin	TCATGAAGTGTGACGTGGACAT	CTCAGGAGGAGCAATGATCTTG

Table S3. The shRNA Sequences

shRNA Name	Sequence
SCR-F	5'-CCGGTCCGGTTCTCCGAACGTGTCACGTCTCGAGACGTGACACGTT CGGAGAATTTTTGG-3'
SCR-R	5'-AATTCCAAAAATTCTCCGAACGTGTCACGTCTCGAGACGTGACACG TTCGGAGAACCGGA-3'
sh-U-F	5'-CCGGTCCGGGCAGATATCTCAGGGCTAACTCGAGTTAGCCCTGAGAT ATCTGCTTTTTGG-3'
sh-U-R	5'-AATTCCAAAAAGCAGATATCTCAGGGCTAACTCGAGTTAGCCCTGAG ATATCTGCCCGGA-3'

Table S4. The primers for UBAP2L Expression Plasmid (ex-U)

Name	Forward Primer (5'→3')	Reverse Primer (5'→3')
UBAP2L	CCCAAGCTTATGATGACATCGGTG	CCGCTCGAGTCAGTTGGCCCCCAG
CDS	GCGACTAAC	CTGTAGCT

Table S5. The primers for construction of Enhancer Plasmids

Name	Forward Primer (5'→3')	Reverse Primer (5'→3')
Amplified from genomic DNA		
1q22-Enh	CGGGGTACCCGCTGGAGCGTGTATAT TCAACC	CGGCTCGAGCCACTACCTCAATTCA GGCGATC
rs2049805 site-directed mutagenesis		
rs2049805	TTACCAACCATACCCATTATTCAAG GTCCTGCTT	AAGCAGGACCTTGAATAATGGGGTA TGGTTGGTAA
rs2974931 site-directed mutagenesis		
rs2974931	TCAAGCAATTCTCCTCCTTCAGCCTC CCAAG	CTTGGGAGGCTGAAGGAGGAGAAT TGCTTGA

Table S6. The primers for amplification of DNA fragments including risk SNPs

Name	Forward Primer (5'→3')	Reverse Primer (5'→3')
rs2075570	G TTCCTTGCTGTACCTCCAC	AGCCACCCATTACCCTCT
rs2049805+ rs2974931	CGCTGGAGCGTGTATATTCAACC	CCACTACCTCAATTCAGGCGATC

Table S7. The primers used in 3C assays

Name	Forward Primer (5'→3')
Primer A	GTTCCCCCTCTCTTTATTTTCAC
Primer B	GCACACTACTGTTTCATTGCCTG
Primer C	TGGTGGTAGACTTTTAGTAGGTGC
Primer D	TGAACAGAGCTTTTTGTTTCCG